The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.
Gene Holdings Inc. remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid. Learn more about ENGN stock here.
Cancer mortality rates continue to fall in Canada, driven by decreases in the death rates from lung and colorectal cancer, ...
-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
San Diego YouTuber Mikey Rijavec is reportedly missing after he issued a mayday call while he was 8 miles away from the ...
Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid ...
Home as We Make It on MSN
Human Foods That Are Safe for Pets
Sharing meals with our pets is considered instinctive, but not all human food ends up in their bowls. Some are toxic or...
Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
Discover a study on perioperative hypothermia in older urology patients, comparing remimazolam and sevoflurane for better ...
The conclusion of the FUTURE study1 by Mohamed Abdel-Fattah and colleagues—that routine urodynamics in women with refractory overactive bladder (r-OAB) is unjustified—is unsurprising. What is ...
Belén Garijo is a Spanish former doctor running a German pharmaceuticals business called Merck. Her $62 billion company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback